Diabetes is a common and a serious global health problem, currently affecting an estimated
8.3% of adults - 382 million people worldwide, and taking up 11% of international health
expenditure (International Diabetes Federation, 2013). Type 2 diabetes is the commonest type
of diabetes and accounts for around 90% of cases. This condition typically develops during
adulthood, usually in people over the age of 40 years, but younger onset is becoming
increasingly more common. The disease is characterised by poorly regulated blood glucose
levels, which may arise from defects in insulin secretion (insulin deficiency), or in its action
(insulin resistance), or both. Therefore, the aim of treatment is to manage blood glucose
levels to alleviate short-term symptoms and prevent or delay the development of long-term
complications. Raised glucose in the blood, known as hyperglycaemia can initially be
controlled by lifestyle management such as changes to diet and exercise, but given the
progressive nature of type 2 diabetes it is likely that most individuals will ultimately require
pharmacological intervention as well. This may initially be with oral hypoglycaemic drugs to
increase the production or uptake of insulin and, if the disease remains uncontrolled, insulin
therap
